Humana (NYSE:HUM – Get Free Report) had its target price boosted by research analysts at Guggenheim from $471.00 to $521.00 in a research report issued on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the insurance provider’s stock. Guggenheim‘s price objective points to a potential upside of 20.13% from the company’s previous close.
Other equities research analysts also recently issued reports about the stock. Monness Crespi & Hardt raised shares of Humana to a “buy” rating in a research note on Friday, October 9th. Zacks Research lowered shares of Humana from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 11th. Mizuho boosted their price target on shares of Humana from $468.00 to $495.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 13th. Deutsche Bank Aktiengesellschaft began coverage on shares of Humana in a report on Thursday, July 30th. They issued a “hold” rating on the stock. Finally, Weiss Ratings upgraded shares of Humana from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, August 14th. Twenty-one investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Humana presently has a consensus rating of “Moderate Buy” and an average target price of $462.87.
View Our Latest Stock Analysis on Humana
Humana Price Performance
Shares of HUM traded down $0.05 during mid-day trading on Monday, reaching $433.69. 637,112 shares of the stock traded hands, compared to its average volume of 1,637,193. The company has a market cap of $52.08 billion, a price-to-earnings ratio of 42.32, a price-to-earnings-growth ratio of 2.67 and a beta of 0.65. Humana has a 1 year low of $163.11 and a 1 year high of $456.50. The firm has a fifty day moving average price of $403.96 and a 200 day moving average price of $312.27. The company has a current ratio of 1.65, a quick ratio of 1.74 and a debt-to-equity ratio of 0.61.
Humana (NYSE:HUM – Get Free Report) last issued its quarterly earnings data on Friday, November 6th. The insurance provider reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.30. The company had revenue of $41.16 billion for the quarter, compared to the consensus estimate of $40.87 billion. Humana had a return on equity of 8.50% and a net margin of 0.81%. The firm’s revenue was up 26.1% compared to the same quarter last year. During the same quarter last year, the business posted $3.24 earnings per share. Humana has set its FY 2026 guidance at 9.500- EPS. As a group, equities research analysts predict that Humana will post 9.03 earnings per share for the current year.
Hedge Funds Weigh In On Humana
A number of large investors have recently modified their holdings of HUM. Diversified Trust Co grew its position in shares of Humana by 23.2% in the 3rd quarter. Diversified Trust Co now owns 4,041 shares of the insurance provider’s stock worth $1,542,000 after buying an additional 760 shares during the period. Moors & Cabot Inc. lifted its position in Humana by 4.3% during the 3rd quarter. Moors & Cabot Inc. now owns 804 shares of the insurance provider’s stock valued at $307,000 after acquiring an additional 33 shares during the period. Allworth Financial LP lifted its position in Humana by 51.1% during the 3rd quarter. Allworth Financial LP now owns 2,658 shares of the insurance provider’s stock valued at $1,056,000 after acquiring an additional 899 shares during the period. Russell Investments Group Ltd. lifted its position in Humana by 9.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 413,336 shares of the insurance provider’s stock valued at $158,101,000 after acquiring an additional 34,831 shares during the period. Finally, Eurizon Capital SGR S.p.A. boosted its stake in Humana by 1.5% during the third quarter. Eurizon Capital SGR S.p.A. now owns 21,164 shares of the insurance provider’s stock worth $8,078,000 after acquiring an additional 303 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.
About Humana
Humana Inc is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans.
The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.
Humana was founded in 1961 as a nursing home company and later expanded into health insurance.
Further Reading
- Five stocks we like better than Humana
- America’s Rare Earth Clock Is Running Out, But the Bottleneck Isn’t Where You Think
- Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength Remains
- Lemonade’s Revenue Soars 73%—So Why Did Its Stock Turn Sour After Earnings?
- Anthropic’s S-1 Strengthens the Case for Broadcom’s AI Growth
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.
